[PART I—FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%E2%80%94FINANCIAL%20INFORMATION) This section presents the unaudited financial statements, management's discussion and analysis, market risk disclosures, and controls and procedures for the company [Item 1. Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed financial statements for Tenaya Therapeutics, Inc. as of June 30, 2023, including balance sheets, statements of operations, stockholders' equity, and cash flows, reporting a **$65.0 million** net loss and **$151.6 million** in cash and equivalents Condensed Balance Sheet Summary (in thousands) | Account | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Total Current Assets** | $138,906 | $193,754 | | Cash and cash equivalents | $75,565 | $95,272 | | **Total Assets** | $220,754 | $278,945 | | **Total Current Liabilities** | $20,917 | $24,248 | | **Total Liabilities** | $30,814 | $35,569 | | **Total Stockholders' Equity** | $189,940 | $243,376 | Condensed Statement of Operations Summary (in thousands) | Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $26,477 | $20,876 | $52,082 | $45,031 | | General and administrative | $8,627 | $7,743 | $16,745 | $14,742 | | **Loss from operations** | $(35,104) | $(28,619) | $(68,827) | $(59,773) | | **Net loss** | $(33,269) | $(28,397) | $(65,006) | $(59,453) | Condensed Statement of Cash Flows Summary (Six Months Ended June 30, in thousands) | Cash Flow Activity | 2023 | 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | $(56,510) | $(54,186) | | Net cash provided by investing activities | $33,146 | $46,644 | | Net cash provided by financing activities | $3,678 | $275 | | **Net change in cash, cash equivalents and restricted cash** | $(19,686) | $(7,267) | - As of June 30, 2023, the company had an accumulated deficit of **$344.2 million** and held **$151.6 million** in cash, cash equivalents, and marketable securities; management believes these funds are sufficient to support operations for at least the next twelve months[28](index=28&type=chunk)[29](index=29&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section analyzes the company's financial condition and operations, detailing its clinical-stage biotechnology business, lead product candidates, increased operating expenses, and liquidity, confirming sufficient funds for the next twelve months - Tenaya is a clinical-stage biotechnology company focused on developing curative therapies for heart disease, with a pipeline including gene therapies and small molecules[73](index=73&type=chunk) - Lead product candidates include: **TN-201** (gene therapy for HCM, Phase 1b trial expected Q3 2023, data 2024); **TN-301** (small molecule for HFpEF, Phase 1 topline data Q4 2023); **TN-401** (gene therapy for ARVC, IND submission expected H2 2023)[75](index=75&type=chunk)[76](index=76&type=chunk)[78](index=78&type=chunk)[79](index=79&type=chunk) - The company has established an in-house cGMP manufacturing facility, the Genetic Medicines Manufacturing Center, to support its portfolio of gene therapy and cellular regeneration candidates[82](index=82&type=chunk) - As of June 30, 2023, the company had **$151.6 million** in cash, cash equivalents, and marketable securities, believed sufficient to fund operations for at least the next twelve months[98](index=98&type=chunk)[101](index=101&type=chunk) [Results of Operations](index=19&type=section&id=Results%20of%20Operations) Operating expenses and net loss increased for both three and six-month periods ended June 30, 2023, primarily driven by higher research and development and general and administrative expenses Comparison of Three Months Ended June 30, 2023 and 2022 (in thousands) | Metric | 2023 | 2022 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Research and development | $26,477 | $20,876 | $5,601 | 27% | | General and administrative | $8,627 | $7,743 | $884 | 11% | | **Total operating expenses** | $35,104 | $28,619 | $6,485 | 23% | | **Net loss** | $(33,269) | $(28,397) | $(4,872) | 17% | Comparison of Six Months Ended June 30, 2023 and 2022 (in thousands) | Metric | 2023 | 2022 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Research and development | $52,082 | $45,031 | $7,051 | 16% | | General and administrative | $16,745 | $14,742 | $2,003 | 14% | | **Total operating expenses** | $68,827 | $59,773 | $9,054 | 15% | | **Net loss** | $(65,006) | $(59,453) | $(5,553) | 9% | - The increase in R&D expenses for the six months ended June 30, 2023, was primarily driven by a **$5.7 million** increase in employee-related costs (higher stock-based compensation and 2022 tax credits) and a **$2.0 million** increase in facility and laboratory costs[94](index=94&type=chunk)[97](index=97&type=chunk) [Liquidity and Capital Resources](index=22&type=section&id=Liquidity%20and%20Capital%20Resources) The company primarily funds operations through equity sales, holding **$151.6 million** in cash and equivalents as of June 30, 2023, with recent capital raises including a **$76.9 million** offering and **$3.9 million** from an ATM offering, sufficient for the next twelve months but requiring future funding - The company completed an underwritten public offering in November 2022, receiving total net proceeds of **$76.9 million**[99](index=99&type=chunk) - Through its "at-the-market" (ATM) equity offering, the company sold 535,767 shares during Q2 2023, resulting in proceeds of **$3.9 million**, net of commissions[100](index=100&type=chunk) - Net cash used in operating activities was **$56.5 million** for the first six months of 2023, compared to **$54.2 million** for the same period in 2022, primarily driven by the net loss[105](index=105&type=chunk)[106](index=106&type=chunk)[107](index=107&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=24&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, the company is exempt from providing quantitative and qualitative disclosures about market risk - As a smaller reporting company, Tenaya Therapeutics is not required to provide quantitative and qualitative disclosures about market risk[119](index=119&type=chunk) [Item 4. Controls and Procedures](index=24&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2023, with no material changes in internal control over financial reporting during the quarter - Management concluded that as of the end of the period, the company's disclosure controls and procedures are effective to provide reasonable assurance that required information is recorded, processed, and reported in a timely manner[120](index=120&type=chunk) - There were no changes in internal control over financial reporting during the quarter ended June 30, 2023, that have materially affected, or are reasonably likely to materially affect, internal controls[121](index=121&type=chunk) [PART II—OTHER INFORMATION](index=26&type=section&id=PART%20II%E2%80%94OTHER%20INFORMATION) This section covers legal proceedings, risk factors, unregistered sales of equity securities, and other miscellaneous information including exhibits [Item 1. Legal Proceedings](index=26&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings expected to adversely affect its business - The company is not currently involved in any material legal proceedings[125](index=125&type=chunk) [Item 1A. Risk Factors](index=26&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant investment risks, including the company's early development stage, history of losses, need for capital, uncertain drug development, manufacturing challenges, competition, and intellectual property concerns - The company is in the early stages of development with a limited operating history, has only completed one clinical trial, and has no products approved for commercial sale[127](index=127&type=chunk)[128](index=128&type=chunk) - The company has a history of significant net losses (**$344.2 million** accumulated deficit as of June 30, 2023) and expects to continue incurring losses for the foreseeable future[127](index=127&type=chunk)[131](index=131&type=chunk) - Substantial additional capital is required to finance operations; failure to raise capital when needed could force the company to delay, reduce, or eliminate research and development programs[127](index=127&type=chunk)[137](index=137&type=chunk) - Drug development is a lengthy, expensive, and uncertain process; preclinical and clinical trials may not demonstrate the required safety and efficacy, and early positive results may not be predictive of future success[127](index=127&type=chunk)[164](index=164&type=chunk) - The company faces risks related to manufacturing its complex gene therapy products, both in-house and through third parties, and must comply with significant government regulations (cGMP)[127](index=127&type=chunk)[198](index=198&type=chunk)[203](index=203&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=73&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered equity sales occurred during the period, and the **$188.5 million** net proceeds from the August 2021 IPO remain unchanged in their planned use - There were no sales of unregistered securities in the period[386](index=386&type=chunk) - The company's IPO on August 3, 2021, generated net proceeds of **$188.5 million**; there has been no material change in the planned use of these proceeds[387](index=387&type=chunk) [Item 3. Defaults Upon Senior Securities](index=73&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This section is not applicable to the company [Item 4. Mine Safety Disclosures](index=73&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company [Item 5. Other Information](index=73&type=section&id=Item%205.%20Other%20Information) No other information is reported in this section [Item 6. Exhibits](index=74&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including bylaws, compensation plans, officer certifications, and XBRL data files [Signatures](index=76&type=section&id=SIGNATURES) This section contains the required signatures for the filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-3789973 (St ...

13 MyPeak-1 Phase 1b Clinical Study TN-201 for MYBPC3 HCM 70%nonobstructive 30%obstructive Disease severity higher with pathogenic sarcomeric gene mutations such as MYBPC3, but no treatments address underlying genetic cause1 Characteristics Symptoms Disease burden • Thickening of left ventricle (hypertrophy) due to excessive contraction • May be characterized as "obstructive" or "nonobstructive" based on location of thickening • Shortness of breath, fainting, chest pain, fatigue, palpitations and arrhythmia ...

Part I [Business](index=6&type=section&id=Item%201.%20Business) Tenaya Therapeutics is a clinical-stage biotechnology company developing curative therapies for heart disease using gene therapy, cellular regeneration, and precision medicine platforms - Tenaya is a clinical-stage biotechnology company focused on developing curative therapies for heart disease, the leading cause of death globally[16](index=16&type=chunk) - The company's strategy is built upon three distinct product platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine, supported by five core internal capabilities[20](index=20&type=chunk)[28](index=28&type=chunk)[31](index=31&type=chunk) Product Pipeline Overview | Program | Indication(s) | Stage | US Prevalence | Commercial Rights | | :--- | :--- | :--- | :--- | :--- | | **TN-201** | MYBPC3+ HCM | Phase 1 | > 115K | Tenaya | | **TN-301** | HFpEF | Phase 1 | > 3MM | Tenaya | | **TN-401** | PKP2+ ARVC | Preclinical | > 70K | Tenaya | | **DWORF** | DCM and/or HFrEF | Research | Prevalent | Tenaya | | **Reprogramming** | Post-MI Heart Failure | Research | Prevalent | Tenaya | [Our Programs](index=14&type=section&id=Our%20Programs) The company's pipeline includes lead candidates TN-201 (HCM), TN-301 (HFpEF), and TN-401 (ARVC), alongside early-stage gene therapy and cellular reprogramming programs - **TN-201 (MYBPC3-associated HCM):** Received IND clearance for a Phase 1b clinical trial, with patient dosing expected in Q3 2023 and data in 2024[66](index=66&type=chunk)[67](index=67&type=chunk) - **TN-301 (HDAC6 Inhibitor for HFpEF):** Currently in a Phase 1 clinical trial, with SAD stage complete and MAD stage initiated in February 2023, and data expected in 2H 2023[86](index=86&type=chunk) - **TN-401 (PKP2-associated ARVC):** IND-enabling activities are underway, with IND submission planned for 2H 2023[130](index=130&type=chunk) - **Early-Stage Programs:** Include a DWORF gene therapy for DCM and a cellular reprogramming therapy for post-MI heart failure, both at candidate selection stage[131](index=131&type=chunk)[148](index=148&type=chunk) [Our Product Platforms and Core Capabilities](index=40&type=section&id=Our%20Product%20Platforms%20and%20Core%20Capabilities) Tenaya's innovation is driven by integrated Gene Therapy, Cellular Regeneration, and Precision Medicine platforms, supported by five core in-house capabilities including disease models and cGMP manufacturing - **Gene Therapy Platform:** Utilizes AAVs to deliver healthy genes to heart cells, enhanced by internal capsid engineering for improved heart targeting[29](index=29&type=chunk)[168](index=168&type=chunk)[172](index=172&type=chunk) - **Cellular Regeneration Platform:** Focuses on in vivo reprogramming of cardiac fibroblasts into new cardiomyocytes to replace cells lost due to disease[32](index=32&type=chunk)[178](index=178&type=chunk) - **Precision Medicine Platform:** Employs human genetic data with iPSC-cardiomyocyte models and machine learning to identify novel heart disease targets[32](index=32&type=chunk)[185](index=185&type=chunk) - **Core Capabilities:** Five key internalized capabilities, including Disease Models and Manufacturing, aim to accelerate development and reduce third-party reliance[31](index=31&type=chunk)[191](index=191&type=chunk)[193](index=193&type=chunk) [Competition, IP, and Manufacturing](index=51&type=section&id=Competition,%20IP,%20and%20Manufacturing) Tenaya faces competition in heart disease therapies, protects its innovations with patents, and has in-house cGMP manufacturing for gene therapies while using CDMOs for small molecules - Key competitors include Bristol Myers Squibb for oHCM, Novartis and Eli Lilly for HFpEF, and preclinical gene therapy programs for ARVC[221](index=221&type=chunk)[222](index=222&type=chunk)[224](index=224&type=chunk) - The company's IP portfolio includes issued U.S. patents and pending applications for its programs, with expirations between 2037 and 2043[228](index=228&type=chunk)[229](index=229&type=chunk)[232](index=232&type=chunk) - Tenaya has internalized AAV manufacturing with non-GMP, technology development, and cGMP facilities, including a 1000L GMMC for clinical and commercial supply[217](index=217&type=chunk)[223](index=223&type=chunk) [Government Regulation](index=55&type=section&id=Government%20Regulation) The company's products are subject to extensive FDA and international regulation, involving complex approval processes for biologics and small molecules, with potential for expedited pathways and significant post-approval reimbursement challenges - In the U.S., biologic products require a BLA and small molecules an NDA from the FDA, involving extensive preclinical and clinical data for approval[247](index=247&type=chunk)[248](index=248&type=chunk) - The company may seek expedited development pathways like Fast Track and Breakthrough Therapy designations to accelerate review for serious conditions with unmet needs[272](index=272&type=chunk)[275](index=275&type=chunk) - Orphan Drug Designation grants seven years of market exclusivity for diseases affecting fewer than **200,000** people, a designation received by TN-201 and TN-401[267](index=267&type=chunk)[269](index=269&type=chunk)[455](index=455&type=chunk) - Commercial success depends on third-party payor reimbursement, with recent legislation like the IRA introducing Medicare price negotiation and inflation rebates that could impact revenue[316](index=316&type=chunk)[323](index=323&type=chunk) [Risk Factors](index=71&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant financial, development, regulatory, manufacturing, competition, and intellectual property risks due to its early stage, lack of revenue, and need for substantial capital - **Financial Risks:** The company has a history of significant net losses, **$123.7 million** in 2022, and requires substantial additional capital, risking program delays or elimination[341](index=341&type=chunk)[347](index=347&type=chunk) - **Development & Regulatory Risks:** Product candidates are early-stage with unproven mechanisms, facing complex and uncertain gene therapy regulations, and preclinical results may not predict clinical success[357](index=357&type=chunk)[363](index=363&type=chunk)[373](index=373&type=chunk) - **Manufacturing & Commercialization Risks:** Gene therapy manufacturing is complex with limited company experience, risking production problems and potential lack of market acceptance or adequate reimbursement post-approval[410](index=410&type=chunk)[412](index=412&type=chunk)[422](index=422&type=chunk) - **Intellectual Property Risks:** Success depends on obtaining and defending patents, with risks of infringement claims from third parties and inability to protect trade secrets[515](index=515&type=chunk)[526](index=526&type=chunk) [Properties](index=129&type=section&id=Item%202.%20Properties) Tenaya Therapeutics leases its corporate headquarters in South San Francisco and a manufacturing facility in Union City, CA, with leases expiring in 2025 and 2031 respectively - Corporate headquarters are leased in South San Francisco, CA, approximately **32,370 sq. ft.**, with the lease expiring on May 31, 2025[627](index=627&type=chunk) - A manufacturing and office facility is leased in Union City, CA, with its lease expiring in July 2031[628](index=628&type=chunk) [Legal Proceedings](index=129&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings expected to adversely affect its business - As of the filing date, the company is not involved in any material legal proceedings[629](index=629&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=130&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity,%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on Nasdaq under "TNYA" since its 2021 IPO, has never paid dividends, and generated **$188.5 million** in net IPO proceeds - The company's common stock trades on the Nasdaq Global Select Market under the symbol **"TNYA"**[633](index=633&type=chunk) - The company has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future[635](index=635&type=chunk) - Net proceeds from the Initial Public Offering (IPO) on August 3, 2021, were **$188.5 million** after deducting offering expenses[638](index=638&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=131&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Tenaya reported a **$123.7 million** net loss in 2022, a **70%** increase from 2021, driven by higher R&D and G&A expenses, with **$204.2 million** in cash expected to fund operations for at least 12 months [Results of Operations](index=132&type=section&id=Results%20of%20Operations) Total operating expenses increased **73%** to **$125.6 million** in 2022, driven by a **74%** rise in R&D and a **69%** rise in G&A, resulting in a **$123.7 million** net loss Results of Operations Summary (2022 vs. 2021) (in thousands) | (in thousands) | 2022 | 2021 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Research and development | $94,537 | $54,393 | $40,144 | 74% | | General and administrative | $31,084 | $18,413 | $12,671 | 69% | | **Total operating expenses** | **$125,621** | **$72,806** | **$52,815** | **73%** | | Loss from operations | ($125,621) | ($72,806) | ($52,815) | 73% | | **Net loss** | **($123,665)** | **($72,721)** | **($50,944)** | **70%** | - Research and development expenses increased by **$40.1 million (74%)** in 2022, driven by higher outside services, personnel costs, and facility expenses[655](index=655&type=chunk)[659](index=659&type=chunk) - General and administrative expenses increased by **$12.7 million (69%)** in 2022, primarily due to higher employee-related expenses, professional services, and insurance costs[658](index=658&type=chunk) [Liquidity and Capital Resources](index=134&type=section&id=Liquidity%20and%20Capital%20Resources) As of December 31, 2022, the company held **$204.2 million** in cash, cash equivalents, and marketable securities, bolstered by a **$76.9 million** follow-on offering, expected to fund operations for at least 12 months - As of December 31, 2022, the company held **$204.2 million** in cash, cash equivalents, and marketable securities[663](index=663&type=chunk) - In November 2022, the company completed a follow-on public offering, raising total net proceeds of **$76.9 million**[664](index=664&type=chunk) - Management believes existing cash is sufficient to fund operations through at least the next twelve months from the report filing date[667](index=667&type=chunk) Cash Flow Summary (2022 vs. 2021) (in thousands) | (In thousands) | 2022 | 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(104,424) | $(60,812) | | Net cash provided by (used in) investing activities | $83,652 | $(238,564) | | Net cash provided by financing activities | $77,767 | $208,970 | [Financial Statements and Supplementary Data](index=140&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) Audited financial statements for 2022 and 2021 are presented, showing total assets of **$278.9 million** and a net loss of **$123.7 million** in 2022, with notes detailing accounting policies and commitments Key Balance Sheet Data (as of Dec 31) (in thousands) | (In thousands) | 2022 | 2021 | | :--- | :--- | :--- | | Cash, cash equivalents & marketable securities | $204,230 | $251,300 | | Total current assets | $193,754 | $255,358 | | Total assets | $278,945 | $314,189 | | Total current liabilities | $24,248 | $21,774 | | Total liabilities | $35,569 | $35,663 | | Total stockholders' equity | $243,376 | $278,526 | Key Statement of Operations Data (Year Ended Dec 31) (in thousands) | (in thousands) | 2022 | 2021 | | :--- | :--- | :--- | | Research and development | $94,537 | $54,393 | | General and administrative | $31,084 | $18,413 | | **Loss from operations** | **($125,621)** | **($72,806)** | | **Net loss** | **($123,665)** | **($72,721)** | | Net loss per share | ($2.76) | ($4.10) | [Controls and Procedures](index=163&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and internal control over financial reporting were effective as of December 31, 2022, with no attestation report required as an emerging growth company - Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2022[818](index=818&type=chunk) - Management concluded that the company's internal control over financial reporting was effective as of December 31, 2022, based on the COSO framework[819](index=819&type=chunk) - No material changes in internal control over financial reporting occurred during the fourth quarter of 2022[821](index=821&type=chunk) Part III [Directors, Executive Officers, Corporate Governance, Executive Compensation, and Other Matters](index=165&type=section&id=Items%2010-14) Information for Items 10 through 14, covering directors, executive officers, corporate governance, and compensation, is incorporated by reference from the company's definitive Proxy Statement - Information for Items 10 through 14 is incorporated by reference from the company's definitive Proxy Statement for its 2022 Annual Meeting of Stockholders[826](index=826&type=chunk)[828](index=828&type=chunk)[831](index=831&type=chunk) Part IV [Exhibits, Financial Statement Schedules](index=166&type=section&id=Item%2015.%20Exhibits,%20Financial%20Statement%20Schedules) This section lists all documents filed as part of the Annual Report on Form 10-K, including financial statements and an index of exhibits - This section contains the list of financial statements and an index of all exhibits filed as part of the 10-K report[834](index=834&type=chunk)[836](index=836&type=chunk)

| --- | --- | --- | --- | --- | |-------------------------------------|-------|-------|-------|-------| | | | | | | | in the Fight Against Heart Disease | | | | | | | | | | | | Corporate Presentation | | | | | | September 2022 | | | | | | | | | | | | | | | | | Forward-looking Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our manag ...

| --- | --- | --- | --- | --- | |-------------------------------------|-------|-------|-------|-------| | | | | | | | in the Fight Against Heart Disease | | | | | | | | | | | | Corporate Presentation | | | | | | September 2022 | | | | | | | | | | | | | | | | | Forward-looking Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our manag ...

| --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | Forward-looking Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertaint ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-40656 TENAYA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

Company Vision and Mission - The company's vision is to transform and extend the lives of people and families fighting heart disease[6] - The company's mission is to discover, develop, and deliver curative therapies that address the underlying causes of heart disease[6] Pipeline and Programs - The company expects to file INDs for TN-201 and TN-301 in the second half of 2022[13] - TN-201, an AAV-based gene therapy for genetic Hypertrophic Cardiomyopathy (gHCM), targets over 115,000 patients in the US[20, 40] - TN-301, a small molecule HDAC6i program, addresses Heart Failure with Preserved Ejection Fraction (HFpEF), affecting over 3 million patients in the US[20, 64] - TN-401, a PKP2 gene therapy program for genetic Arrhythmogenic RV Cardiomyopathy (gARVC), targets over 70,000 patients in the US[20, 93] Capabilities and Foundations - The company has established >40 human iPSC-derived cardiomyocyte (iPSC-CM) models mimicking human disease phenotypes[23] - The company screened >1 billion capsids from >30 libraries for capsid engineering[23] - The company's cash balance of $2513 million is sufficient to fund operations at least into the second half of 2023[125, 126]